Two-Part CE Webinar

Join us for this two-part CE webinar on the latest updates in interstitial lung disease. Each session will be offered twice and will feature a live faculty question-and-answer. Register now to save your virtual seat!

SESSION 1

Wednesday, March 3, 2021
12:00 pm – 1:30 pm ET
or
Tuesday, March 16, 2021
8:00 pm – 9:30 pm ET

Topics

  • Understanding IPF and Non-IPF ILDs: What’s New in Diagnosis and Classification
  • Long-Term and Real-World Studies in IPF – What Can We Learn?
  • Clinical Cases
  • LIVE Question & Answer

SESSION 2

Wednesday, March 10, 2021
8:00 pm – 9:30 pm ET
or
Tuesday, March 23, 2021
12:00 pm – 1:30 pm ET

Topics

  • Updates in Non-IPF ILD
  • Clinical Cases
  • Current Challenges and Future Directions in ILD and IPF
  • LIVE Question & Answer

Series Overview

Interstitial lung disease (ILD) encompasses a large group of pulmonary conditions characterized by tissue scarring, or fibrosis. Lung damage associated with ILD is often irreversible and may be progressive. Various causes have been identified, including long-term exposure to hazardous materials (eg, asbestos); bacterial, viral, and fungal infections; and autoimmune connective tissue diseases affecting the lung. In some cases, the underlying cause remains unidentified. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, but there is a large and diverse group of patients who develop a progressive fibrosing phenotype of ILD (PF-ILD) who do not meet IPF diagnostic criteria but have a similar natural history and prognosis. Historically, treatment options for ILD have been limited, but new agents and indications have been approved in recent years. It is critical that pulmonologists, rheumatologists, and other providers who care for patients with ILD are aware of the latest clinical evidence on optimal treatment approaches for various ILD subtypes. In this two-part educational forum including clinical cases, expert clinicians will discuss the latest evidence-based approaches to diagnosis, classification, and management of patients with ILD. Faculty also will review clinical trial and real-world data to support optimal treatment and improved outcomes for patients with ILD.


CE Information

Target Audience

The intended audience for this activity is pulmonologists, rheumatologists, internists, radiologists, nurse practitioners, physician assistants and other health care professionals involved in the management of patients with ILD.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Session 1

  • Apply the latest technologies and guidelines to the timely recognition of patients with ILD as well as the accurate determination of subtype.
  • Apply knowledge of the latest long-term and real-world evidence to the early and sustained treatment of patients with IPF.
  • Assess the latest clinical evidence regarding the treatment of patients with ILD.

Session 2

  • Assess the latest clinical evidence regarding the treatment of patients with ILD.
  • Identify patients with worsening PF-ILD who may benefit from new treatment options.
  • Utilize a multidisciplinary care team, including the patient, to optimize outcomes for patients with ILD.

For more session-specific CE information, please visit the registration sites.